Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078682 | 1.00 | BRD4 (0.41) | BRD4CREBBPGLSHRH1MAOA | |
| SCHEMBL23960541 | 0.89 | NAMPT (0.44) | MAOANAMPTHDAC1KDM1AMAOB | |
| SCHEMBL23932334 | 0.88 | HRH1 (0.44) | HRH1MAOAKDM1AMAOBJAK3 | |
| SCHEMBL23960608 | 0.87 | BRD4 (0.39) | BRD4CREBBPGLSHRH1NAMPT | |
| SCHEMBL30151671 | 0.87 | BRD4 (0.39) | BRD4CREBBPGLSHRH1NAMPT | |
| SCHEMBL23960643 | 0.79 | F2R (0.52) | ROCK2 | |
| SCHEMBL30151697 | 0.79 | F2R (0.52) | ROCK2 | |
| SCHEMBL30636560 | 0.79 | F2R (0.52) | ROCK2 | |
| SCHEMBL23960647 | 0.77 | SLC6A4 (0.43) | HRH1MAOAKDM1AMAOB | |
| SCHEMBL23932419 | 0.76 | HSD17B10 (0.46) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4138824-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | Anovia Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | BRD4 988/4885CREBBP 1574/4885GLS 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.